EGFR and neoplasm: The complex cross-talks among different kinase cascades along with the existing tumor heterogeneity at the genomic and proteomic level and the high probability of mutations, are the cause of resistance to selective EGFR inhibitors and have proved to be a major impediment to achieve the desired results.